Gilead's Lenacapavir Shows High Rates Of Virologic Suppression In Heavily Treated HIV Patients

Gilead Sciences Inc GILD announced new Phase 3 data from the ongoing CAPELLA trial evaluating lenacapavir, its investigational, long-acting HIV-1 capsid inhibitor.
The data were presented at the 11th International AIDS Society (IAS) Conference on HIV Science.
The findings demonstrate that lenacapavir, administered subcutaneously every six months in combination with other antiretrovirals, achieved high rates of virologic suppression at Week 26 in people with multi-drug resistant HIV.
In this patient population, 81% (n=29/36) of participants receiving the lenacapavir combo regimen achieved an undetectable viral load at Week 26.
Last month, Gilead submitted a marketing application to the FDA for lenacapavir.
If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.
The Company also shared announced long-term Biktarvy data showing high efficacy and durable viral suppression in untreated HIV patients.
Price Action: GILD shares closed at $68.63 on Friday.

Overview Rating:

Good

100

0100